Last update Aug. 24, 2022
Compatible
We do not have alternatives for Proconvertin. Serum prothrombin conversion accelerator since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Proconvertin. Serum prothrombin conversion accelerator is also known as Coagulation factor VII. Here it is a list of alternative known names::
Proconvertin. Serum prothrombin conversion accelerator in other languages or writings:
Proconvertin. Serum prothrombin conversion accelerator belongs to this group or family:
Main tradenames from several countries containing Proconvertin. Serum prothrombin conversion accelerator in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | 50.000 | daltons |
VD | 0.002 | l/Kg |
T½ | 3 - 6 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Factor VII is a vitamin K-dependent plasma glycoprotein consisting of 406 amino acids. It is involved in blood coagulation. It can be obtained from human plasma or produced by recombinant DNA technology (Eptacog Alfa). It is used to treat bleeding disorders such as hemophilia, Glanzmann's thrombasthenia, and congenital factor VII deficiency, and in the treatment of severe postpartum hemorrhage unresponsive to uterotonics. Intravenous administration.
Since the last update we have not found published data on its excretion in breastmilk.
Its very high molecular weigh and its binding to coagulation factors X and IX and tissue factor make it highly unlikely that significant quantities will pass into breast milk.
Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.
Expert authors consider the use of this medication probably compatible during breastfeeding. (Hale). Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)